

Supplemental Table 1. General characteristics of included health economic studies (excluding cost-effectiveness analyses)

| No. | Reference | Country | Type of pharmacoeconomic study | Perspective | Population | Discount Rate | Intervention | Comparators | Duration |
|-----|-------------------------------|----------|--------------------------------|-------------------|--|---------------|---------------------|--|-----------------------------------|
| 1 | Peres J. et al., 2017 (34) | Portugal | Cost-utility | Hospital | 6 patients (5 females, 1 male) | N.R. | Rituximab Treatment | Acetylcolinesterase Inhibitors, Plasma exchange (PLEX), Intravenous immunoglobulin (IVIg), Prednisone, Azathioprine, Mycophenolate Mofetil, Cyclosporine | February 2010 - September 2015 |
| 2 | Heatwole C. et al., 2011 (11) | USA | Cost-minimization | Hospital | Patients with Myasthenia Gravis (MG) | N.R | IVIg | PLEX | Duration: 5 days |
| 3 | Bugge C. et al., 2025(30) | Norway | Cost-analysis | Healthcare System | 1083 patients, 155 with IVIg treatment | N.R | IVIg treatment | Non IVIg treatments | 1 January 2010 - 31 December 2021 |

| | | | | | | | | | |
|---|---|--------------------------------|--------------------------|----------------------|---|-----|---|---|--------------------------------------|
| 4 | Philip s G. et al., 2022(12) | USA | Cost- analysis | Healthcare System | 41,940 patients | N.R | Direct cost of gMG standard-of- care therapies and add-on therapies | Full cost of treatment between newly diagnosed, previously diagnosed (PD), exacerbation and crisis event subgroups | 1 January 2014 - 31 December 2019 |
| 5 | Lehn erer S. et al, 2025(28) | Germany | Cost- descriptio n | Healthcare System | 1660 and 750 MG patients | N.R | Total cost of hospitalizati on. | No MG-related treatment; Standard treatment; Intensified treatment | From 2014 to 2019 |
| 6 | Ignat ova V. et al., 2022(35) | Bulgaria | Cost-of- illness | Healthcare System | 54 adult patients | N.R | Direct annual costs of MG | Indirect costs of MG | May 2020 - September 2020 |
| 7 | Piehl F. et al, 2024 (32) | Denmark, Finland, Sweden | Cost- descriptio n | Healthcare System | 8.622 patients with MG; Patients \geq 18 years old with \geq 2 MG diagnosis codes. | 3% | Total hospitalizati on costs, healthcare resource utilization (HCRU), direct medical costs | Indirect societal costs | From 2000 to 2020 |

| | | | | | | | | | |
|----|------------------------------|----------------|------------------|-------------------|--|-----|--|--|-----------------------------------|
| 8 | Doni n G. et al., 2024 (36) | Czech Republic | Cost-description | Healthcare System | Adult patients with MG | N.R | Outpatient Medication Costs | Outpatient IVIg and PLEX Treatment Costs | January 2017 - December 2020 |
| 9 | Chen J. et al., 2020 (24) | China | Cost-description | Healthcare System | 59,243 MG patients | N.R | Total cost of hospitalization | N.R | 1 January 2016 - 31 December 2018 |
| 10 | Castillo R. et al., 2022(13) | USA | Cost-description | Healthcare System | 148 MG patients who received thymectomy. | N.R | Minimally invasive thymectomy (MIS) using video-assisted thoracoscopic surgery (VATS). | Open thymectomy (OT), via sternotomy. | From 2013 to 2018 |
| 11 | Cai Q. et al., 2024 (33) | Sweden | Cost-analysis | Healthcare System | 1275 patients | N.R | All-cause costs, MG-related costs, direct medical costs, indirect costs | Healthcare costs between newly diagnosed patients and patients with preexisting MG | 1 January 2010 - 31 December 2017 |

| | | | | | | | | | |
|----|-------------------------------|--------|-------------------|-------------------|--|-----|--|---|--|
| 12 | Pisc J. et al., 2023 (14) | USA | Cost-analysis | Healthcare System | 3218 patients with MG | N.R | All-cause costs, MG-related costs inpatient and outpatient costs | Healthcare costs between patients with different insurance types (commercial, Medicare, Medicaid) | 1 January 2008 - 30 September 2019 |
| 13 | Souayah N. et al., 2009 (15) | USA | Cost-description | Hospital | 651 patients from 1991-1992; 994 patients from 2001-2002 | N.R | Total cost of hospitalization | N.R | 1991 - 2002 |
| 14 | Antonini G. et al, 2023 (37) | Italy | Cost-description | Healthcare system | 4397 patients | N.R | MG treatments | Non-MG population | January 2011 - December 2018 |
| 15 | Ting A. et al, 2023 (16) | USA | Cost-description | Healthcare system | 1498 adults (aged ≥ 18 years) | N.R | The second-line therapies for MG | N.R | 2 years post-initiation of second-line therapy |
| 16 | Furlan C. J. et al, 2016 (38) | Canada | Cost-minimization | Hospital | 70 patients with MG (32 IVIg; 38 PLEX) | N.R | PLEX | IVIg | 2007 - 2010 |

| | | | | | | | | | |
|----|--|---------|-----------------|----------------------|--|-----|--------------------------------------|--|------------------------------------|
| 17 | Sche pelm ann K. etal, 2010(29) | Germany | Cost-of-illness | Healthcare system | 107 patients diagnosed with ALS, FSHD or MG (18 years of age or older) | N.R | Total annual healthcare costs for MG | N.R | 12-month period |
| 18 | Sonkar KK. etal, 2016 (39) | India | Cost-analysis | Tertiary care center | 66 patients with MG (39 males) | N.R | The direct cost of treatment | Indirect cost of MG | 1 year (2014-2015) |
| 19 | Shen Sh.P. etal, 2023 (25) | Taiwan | Cost-of-illness | Healthcare system | 2537 patients with gMG | N.R | HRU and costs in gMG patients | HRU and costs in individuals without gMG | 01 January 2019 - 31 December 2019 |
| 20 | Shen Sh.P. etal, 2023 (25) | USA | Cost-analysis | Medical/pharmacy | 1,288 patients with MG | N.R | Full costs of treatments | N.R | June 1, 2008-June 30, 2010 |

| | | | | | | | | | |
|----|-------------------------------------|---------|-----------------|-----------------------------|---|-----|---|---|--|
| 21 | Fang W. et al., 2020 (26) | China | Cost-analysis | Hospital/ Healthcare system | 4130 patients with JBI (job based insurance) and 472 with RBI (residence based insurance) | N.R | Medical costs of MG patients with JBI | Medical costs of MG patients with RBI | 17-year period, from 2000 to 2017 |
| 22 | Zhda nava M. et al., 2024 (18) | USA | Cost-analysis | Healthcare system | 2739 patients and 1638 patients diagnosed with generalized myasthenia gravis (gMG) | N.R | Patients with high follow-up costs | Patients with not-high follow-up costs | 1 January 2018-31 December 2021 |
| 23 | Van Enkh uizen J. et al., 2024 (40) | England | Cost-of-illness | Healthcare system | 9087 adult patients with MG | N.R | Treatments used for MG and associated healthcare costs in MG patients | Treatments used for MG and associated healthcare costs in MG patients | Follow up from diagnosis to June 2021 or death |
| 24 | Yu J. et at., 2025 (27) | China | Cost-of-illness | Societal | 1020 patients with MG | N.R | Annual direct costs of MG | Annual indirect costs of MG | 12 months per patient |

| | | | | | | | | | |
|----|----------------------------------|-----|---------------|-------------------|---|-----|--|--|----------------------------------|
| 25 | Gupti II J.T. et al „ 2012 (19) | USA | Cost-analysis | Healthcare system | 113 MG patients and 339 non-MG patients | N.R | IVIg cost | PLEX, pharmacological therapies costs | 2009-2011 |
| 26 | Omor odion J.O. et al, 2017 (20) | USA | Cost-analysis | Healthcare system | Patients hospitalized for MG | N.R | Standard inpatient management, hospital-based care for MG, diagnostic and treatments such as IVIG or plasma exchange | Multiple Sclerosis hospitalizations and all U.S. hospital admissions | 2003-2013 |
| 27 | Zhda nava M. et al ., 2024 (21) | USA | Cost-analysis | Healthcare system | 2,739 patients | N.R | IVIg | Other therapies (Non-steroidal immunosuppressive s , Cholinesterase inhibitors, Corticosteroids) | 1 January 2017 -31 December 2021 |

Abbreviations: gMG-generalized myasthenia gravis; HCRU-healthcare resource utilization; IVIg- Intravenous immunoglobulin; JBI-job based insurance; MIS-Minimally Invasive Surgery; MG- Myasthenia Gravis; N.R-Not reported; OT-Open thymectomy; PLEX-Plasma exchange; RBI-residence based insurance; VATS- video-assisted thoracoscopic surgery.